Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

William Tillett, Alexander Allen, Laura Tucker, David Chandler, Coziana Ciurtin, Charlotte Davis, Andrew Dick, Amy Foulkes, Nicola Gullick, Philip Helliwell, Deepak Jadon, Gareth Jones, Stuart Kyle, Vishnu Madhok, Neil McHugh, Andrew Parkinson, Tim Raine, Stefan Siebert, Catherine Smith, Laura C Coates

Research output: Contribution to journalArticle (Academic Journal)

Abstract

The aim of this guideline is to provide an update on evidence-based recommendations for treatment of adult patients with PsA. The previous BSR guidelines for PsA were published in 2012 and since that time, there have been many new advanced therapies licensed for PsA. This update will provide practical guidance for clinicians on the optimal selection of advanced therapies taking into account different domains of PsA (arthritis, enthesitis, dactylitis, axial disease and psoriasis) and key associated comorbidities. It will also update guidance on treatment strategy including the use of a treat-to-target approach. The guideline will be developed using the methods and processes outlined in Creating Clinical Guidelines: Our Protocol. (1) This development process to produce guidance, advice and recommendations for practice has National Institute for Health and Care Excellence (NICE) accreditation.
Original languageEnglish
Article numberkeaa526
Number of pages5
JournalRheumatology
Early online date23 Oct 2020
DOIs
Publication statusE-pub ahead of print - 23 Oct 2020

Keywords

  • psoriatic_arthritis treatment biologics
  • bDMARDs targeted
  • tsDMARDs guideline management

Fingerprint Dive into the research topics of 'Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope'. Together they form a unique fingerprint.

Cite this